A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date11/4/20 → 10/12/22

Funding

  • Alector LLC: $21,674.00